Flow Cytometry Market: The increasing applications of flow cytometry in healthcare along with the increasing number of cancer cases is projected to boost the market growth at a healthy CAGR of ~ 8.20

Market Research Future (MRFR) has published on the “Global Flow Cytometry Market”.

The global flow cytometry market is projected to register a CAGR of 7.47% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global flow cytometry market Thermo Fisher Scientific, Inc. (US), Beckman Coulter, Inc. (US), Becton, Dickinson, and Company (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), Miltenyi Biotec (Germany), Cytek Biosciences, Inc. (US), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), and Luminex Corporation (US).

Market Highlights

The global flow cytometry market is accounted to register a CAGR of 7.47% during the forecast period and is estimated to reach USD 10.49 billion by 2032.

Cancer, cardiovascular diseases, and others fuel demand for advanced diagnostics like flow cytometry. This technology helps researchers and clinicians understand disease mechanisms, diagnose patients, and monitor treatment. Moreover, flow cytometry's ability to quickly analyze individual cells makes it ideal for POCT settings. This allows faster diagnosis, improves patient management, and decentralizes healthcare services. The COVID-19 pandemic further underscored the importance of rapid POCT, boosting flow cytometry adoption. Also, growing investments in research, particularly in immunology, oncology, and drug discovery, drive flow cytometry advancements. This leads to new instrument development, reagent improvement, and analysis software enhancements, expanding applications and market growth.

Additionally, high costs of instruments and reagents restrain market growth, particularly for resource-constrained settings. However, the development of more affordable instruments and expanding applications in diverse fields like medical diagnostics, drug discovery, and stem cell research present significant opportunities for future market expansion.

Overall, the growing burden of chronic diseases, the shift towards POCT, and increasing R&D investments in flow cytometry are significant drivers propelling market growth. Addressing cost concerns and exploring new applications will be crucial for further market expansion and wider accessibility of this valuable technology.

Access full report @ https://www.marketresearchfuture.com/reports/flow-cytometry-market-6433

Segment Analysis

The global flow cytometry market has been segmented based on component, technology, application, and end user.

On the basis of component, the global flow cytometry market is segmented into cytometry platform, accessories, reagents and consumables, software, and services. Further, the cytometry platform has been bifurcated into cell sorters and cell analyzers; accessories have been further segmented into filter, laser, detectors, and others; and reagents and consumables have been segmented into antibodies, dyes, beads, solution, buffer, and others. The cytometry platform segment accounted for the largest market with a market share of over 30.08% in 2022, and the reagents and consumables segment is anticipated to be the fastest-growing for the forecast period of 2023–2032. This is due to the increasing acquisition in order to meet customers’ demand. For instance, in February 2021, Thermo Fisher Scientific, Inc (US) acquired Cell Sorting Technology from Propel Labs (US), which has enhanced Thermo Fisher Scientific, Inc.'s existing flow cytometry product portfolio. This has had strengthened the provision of powerful sorting capabilities, novel safety features, and faster throughput.

Based on technology, the global flow cytometry market is segmented into bead based flow cytometry and cell based flow cytometry. The cell based flow cytometry segment accounted for the largest market in 2022, and bead based flow cytometry is anticipated to be the fastest-growing for the forecast period of 2023–2032. In several ways, bead-based flow cytometry outperforms cell-based methods. It enables the study multiple targets (up to 50) on a single cell at the same time, providing you with a complete picture of cellular interactions. Further, cell-based flow cytometry demonstrates the microscopic secrets of individual cells, enhancing research and patient care. In milliseconds, it beams a laser on thousands of cells, revealing surface markers, internal proteins, and even activity such as apoptosis. Hence, the wide range of advantages provided by both technologies is propelling the growth of the technology segment.

The flow cytometry market is segmented into academic and clinical research applications and diagnosis applications. Academic and clinical research applications further segmented into cell cycle analysis and cell proliferation, apoptosis, sorting and screening, transfection and cell viability, others and diagnosis applications segmented into cancer immunodeficiency diseases, organ transplantation, and others. The cancer segment is divided into leukemia, lymphoma, and others. The diagnosis applications segment accounted for the largest market with a market share of over 59.09% in 2022. Flow cytometry is transforming the diagnostic landscape by offering detailed insights into the cellular level, leading to more accurate diagnoses, personalized treatment approaches, and improved patient outcomes across a wide range of diseases including immunodeficiency diseases and hematology such as leukemia and lymphoma.

Based on end user, global flow cytometry market is segmented into hospitals & clinics, commercial organizations, medical schools and clinical labs, research institutes, and others. The hospitals & clinics segment accounted for the largest share in 2022 and commercial organizations is the fastest-growing segments during the forecast period. In hospitals and clinics, flow cytometry shines its spotlight in diagnosing cancers, analyzing immune responses, and monitoring treatment effectiveness. Commercial organizations rely on it for drug discovery, optimizing cell-based therapies, and accelerating research. Medical schools and clinical labs use it for training future generations and performing critical clinical tests. Research institutes leverage their power to unravel cellular mysteries in diverse fields like immunology, stem cell research, and neuroscience. Beyond these, flow cytometry finds applications in environmental studies, forensics, and even food safety. Overall, its multi-faceted utility, driven by the rise of chronic diseases, personalized medicine, and technological advancements, ensures its continued growth across various sectors, ultimately benefitting research, diagnosis, and patient care.

Regional Analysis

The global flow cytometry market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. North America further includes US and Canada. Europe includes countries namely Germany, France, UK, Italy, Spain, and the Rest of Europe. The global flow cytometry market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.

North America held the largest market share in terms of revenue in 2022 for its cutting-edge technology. Cutting-edge instruments and innovative reagents fueled its market lead and also, it focuses on advanced technologies like high-speed cell sorters and multispectral analysis powered market growth. Moreover, the launching of novel developments also aids the growth of the studied industry in the region. For instance, in June 2021, Thermo Fisher Scientific introduced the Invitrogen Attune CytPix Flow Cytometer. It is a flow cytomuse with imaging capabilities that uses a high-speed camera and acoustic focusing flow cytometry technology. Users may obtain high-performance fluorescent flow cytometry data from cells while also taking high-resolution brightfield photos with the Attune CytPix. This allows them to compare photos to flow cytometry data in order to better comprehend the form and quality of the cells.

Moreover, Europe shows significant growth during the forecast period. The rise of chronic diseases, like cancer and autoimmune disorders, fuels the demand for advanced diagnostic tools like flow cytometry. This, coupled with a growing need for new technologies in the field, is driving significant market expansion. Additionally, increased investment in research and development further propels market growth by leading to innovative instrumentation and applications. As healthcare spending continues to climb across Europe, both in developed and developing nations, exciting opportunities emerge for companies to develop new flow cytometry solutions and gain a competitive edge in this vibrant market.

Furthermore, the Asia-Pacific flow cytometry region market is the fastest growing and present lucrative growth opportunities for the global market due to booming pharma and biotech in regions like China and India. Rising chronic diseases and expanding applications for cytometry devices fuel the industry. Advancements in cancer, infectious diseases (including COVID-19), and regional research initiatives further propel the market. China, with its rising research interest in multidisciplinary cytometry, and Australia's R&D growth, are key countries driving regional expansion.

The Rest of the World region is comprised of the Middle East, Africa, and Latin America. The rest of the world's flow cytometry market is fueled by rising government support, public-private partnerships, and increased funding. In regions like Mexico, where leishmaniasis cases are spiking, flow cytometry plays a crucial role in determining a patient's prognosis due to new assays for diagnosis and therapy resistance. With the growing leishmaniasis population, as highlighted in a December 2022 Tropical Medicine and Infectious Disease article, demand for flow cytometry for prognosis is poised for significant expansion.

Key Findings of the Study

• The global flow cytometry market is expected to reach USD 10.49 billion by 2032, at a CAGR of 7.47% during the forecast period.


• The Europe region held the second largest market share of the global market, owing to higher adoption of cutting-edge technology and the presence of renowned market players.


• Based on technology, the cell based flow cytometry segment held the largest market with a market share of 55.89% in 2022 and bead based flow cytometry is the fastest-growing segment during the forecast period.


• Thermo Fisher Scientific, Inc. (US), Beckman Coulter, Inc. (US), Becton, Dickinson, and Company (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), Miltenyi Biotec (Germany), Cytek Biosciences, Inc. (US), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), and Luminex Corporation (US) are the key players in the market.